Printer Friendly

I-FLOW INTRODUCES NEW SOFTWARE PROGRAM FOR USE WITH THE VIVUS 4000 AND VIVUS 4000/2 AMBULATORY INFUSION SYSTEMS (Product Announcement)

 I-FLOW INTRODUCES NEW SOFTWARE PROGRAM FOR USE WITH THE
 VIVUS 4000 AND VIVUS 4000/2 AMBULATORY INFUSION SYSTEMS
 IRVINE, Calif., Jan. 6 /PRNewswire/ -- I-FLOW Corporation (NASDAQ: IFLO), manufacturer and seller of technically advanced ambulatory infusion systems, announced today that the U.S. Food and Drug Administration (FDA) granted permission for the company to market a new software program for use with the company's VIVUS 4000 and VIVUS 4000/2 Infusion Systems. The new software provides the infusion systems with additional capabilities and makes them even easier to use.
 I-FLOW introduced the new software product at the recent American Society of Hospital Pharmacists annual meeting, where it received a very favorable reception. "Our new software provides expanded programming capabilities and eliminates the need for a dedicated programmer unit," reported Donald M. Earhart, president and chief executive officer. "Our customers can now use their existing laptop or desktop computers to program I-FLOW infusers. Healthcare professionals will be able to create and modify infusion programs more efficiently, store patient- specific information on existing databases, and link a patient's file information to other internal office computer systems. These additional features will make the VIVUS 4000 and VIVUS 4000/2 Infusion Systems even more cost-efficient and easier to program and use."
 The introduction of the new software strengthens I-FLOW's position as the technology leader in multiple-channel ambulatory infusion systems. This product, the third new product introduced by I-FLOW during the past six months, is scheduled for shipment later this month.
 I-FLOW Corporation is a manufacturer and seller of technically advanced multiple-channel ambulatory infusion systems for use at alternate care sites. The company's products are reliable, easy-to-use and offer its customers significant opportunities to expand their therapy base, increase their quality of care and improve their productivity. These advantages translate into improved revenues and profits for the company's customers while reducing healthcare costs and improving the quality of life for patients.
 -0- 1/6/92
 /CONTACT: Jim Dal Porto of I-FLOW, 714-553-0888, or Jamie Trevor of Corporate Communications Services, 714-435-9737, for I-FLOW/
 (IFLO) CO: I-FLOW Corporation ST: California IN: CPR HEA SU: PDT


CK -- NY007 -- 6794 01/06/92 10:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Article Type:Product Announcement
Date:Jan 6, 1992
Words:356
Previous Article:ABSOLUTE ENTERTAINMENT ANNOUNCES AT '92 WCES STATE-OF-THE-ART HOME VIDEO GAMES COMING TO AMERICAN HOMES THIS YEAR (Product Announcement)
Next Article:INGRAM MICRO WILL DISTRIBUTE OCCAM RESEARCH'S MUSE TO RESELLERS, RETAIL OUTLETS
Topics:


Related Articles
I-FLOW ANNOUNCES FIRST QUARTER INCREASE IN SALES AND UNITS SHIPPED
I-FLOW ACHIEVES SECOND QUARTER REVENUE GROWTH OF 50 PERCENT AND FIRST SHIPMENTS OF DISPOSABLE PUMPS
I-FLOW EXPECTS TO REPORT APPROXIMATELY $2.0 MILLION IN REVENUES FOR THE 1992 YEAR, A 700 PERCENT INCREASE OVER THE PRIOR YEAR
I-FLOW TO REPORT $1.6 MILLION IN REVENUES FOR THE SECOND QUARTER OF 1993, A 434 PERCENT INCREASE OVER THE SAME PERIOD IN THE PRIOR YEAR
SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE PRESENTATION SUMMARY: I-FLOW
SANTA BARBARA GROWTH STOCK CONFERENCE: I-FLOW
I-FLOW CORP. OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE
I-FLOW CORPORATION REPORTS SIGNIFICANT RISE IN SECOND QUARTER REVENUES AND EARNINGS
VIVUS Announces Launch of ACTIS: New Treatment of Impotence - Adjustable Penile Band Available by Prescription
Robert M. Cohen & Co. Reiterates Rating on Vivus; Analyst Continues Speculative Buy and $50-1/2 Price Target

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters